BioCentury | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

...the Genentech Inc. unit of Roche, Chugai Pharmaceutical Co. Ltd. and Curis Inc.; and Odomzo sonidegib...
...treat acute myelogenous leukemia (AML) and pancreatic cancer, and in Phase I testing for myelofibrosis. Odomzo...
BioCentury | Sep 19, 2017
Distillery Therapeutics

Cancer

...testing to treat sarcoma and myelofibrosis. Sun Pharmaceutical Industries Ltd. markets the SMO antagonist Odomzo sonidegib...
BioCentury | Jan 13, 2017
Company News

Sun Pharma, Novartis deal

...Sun Pharma acquired Odomzo sonidegib from Novartis for $175 million up front, plus undisclosed milestones. The...
...AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA), Mumbai, India Business: Cancer Alicia Parker LDE225 Odomzo sonidegib Novartis...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | Jun 13, 2016
Product Development

Basket cases

...mutation Melanoma with BRAF V600E mutation SIGNATURE Product(s) MOA/target Molecular alteration Most advanced indication Odomzo sonidegib...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This...
BioCentury | Oct 5, 2015
Finance

Drawn and quartered

...patients with unresectable or metastatic melanoma Novartis AG (NYSE:NVS; SIX:NOVN) FDA and EC approve Odomzo sonidegib...
BioCentury | Sep 14, 2015
Clinical News

Sonidegib regulatory update

...The European Commission approved Odomzo sonidegib from Novartis to treat adult patients with locally advanced basal...
...Australia for BCC. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Sonidegib ( Odomzo ) ( LDE225...
BioCentury | Aug 3, 2015
Clinical News

Odomzo sonidegib regulatory update

...FDA approved an NDA from Novartis for Odomzo sonidegib to treat adult patients with locally advanced...
...in Switzerland for the indication. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Odomzo sonidegib ( LDE225...
BioCentury | Jul 13, 2015
Clinical News

Sonidegib regulatory update

...EMA’s CHMP recommended approval of Odomzo sonidegib from Novartis to treat patients with locally advanced basal...
...smoothened (SMO) inhibitor. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Sonidegib ( Odomzo ) ( LDE225...
Items per page:
1 - 10 of 31